documents: FDA-2021-D-0691-0013

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2021-D-0691-0013 FDA FDA-2021-D-0691 Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell Death-Ligand 1 Blocking Antibodies for Treatment of Patients With Cancer; Guidance for Industry; Availability Notice Notice of Availability 2022-12-06T05:00:00Z 2022 12 2022-12-06T05:00:00Z   2022-12-06T13:06:58Z 2022-26464 0 0 090000648551cdc8

Links from other tables